UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Life Science

The top 4 challenges for microbiome companies – NIZO

Microbiome research is abundant and profoundly inspiring. Whether focusing on cancer drug response, or the more classical field of gut discomfort solutions, we are clearly on the brink of some long-anticipated breakthroughs. But despite the promise, companies in the field face challenges.

Read More

The promise of AI in medical imaging: improving medical practice

In our lab of Quantitative Imaging and Artificial Intelligence, we’re developing AI applications in a variety of areas, such as radiology and pathology. The goal is to develop applications that meet unmet medical needs, particularly in relation to precision medicine and clinical prediction.

Read More

Blockchain: the missing piece in healthcare’s digital transformation journey?

Blockchain technology is still in its nascency in the healthcare industry. At Frost & Sullivan, we do research and consulting for leading pharmaceutical and diagnostic companies, and the digital solution vendors that are providing Blockchain solutions to end-users.

Read More

Stem cell based anti-NASH drug testing: a pragmatic approach for a complex disease

Non-alcoholic fatty liver disease (NAFLD) ranges from simple hepatic steatosis to severe, life-threatening non-alcoholic steatohepatitis (NASH). Steatosis is mostly asymptomatic and does not cause health complications.

Read More

Empowering patients: creating a healthcare data Blockchain network

Alongside my primary role as a Project Manager, I have since 2016 been the Roche lead for the IMI industry collaboration called EHR4CR. EHR4CR is a group of roughly 10 pharma companies, universities, and SMEs working together to leverage the great wealth of information from hospitals in order to support our clinical trials and promote innovative research. It was a 7-year $16 million project.

Read More

The Genetics of progressive NAFLD

Over the last decade, the understanding of genetic factors impacting progressive liver disease has greatly increased. At the 2nd Global NASH Congress, Associate Professor at the University of Milan, Luca Valenti’s research showed the I148M variant of PNPLA3 to be the main common genetic determinant of NAFLD, and how this discovery can be translated into therapeutic approaches.

Read More

PathLAKE: Benefitting Pathologists with exemplary projects

David Snead is Consultant Histopathologist and Clinical lead for Coventry and Warwickshire Pathology Services (CWPS), a network of labs hosted by University Hospitals of Coventry and Warwickshire NHS Trust. As head of the UHCW Digital Pathology Centre of Excellence, he is now heavily involved in the Pathology image data Lake for Analytics, Knowledge, and Education (PathLAKE).

Read More

Predicting future threats by approaching CyberSecurity from all angles

Merck, Sharp & Dohme operates a hub model with IT hubs in the US, Czech Republic, and Singapore.

All operations and important functions of IT are distributed within those three hubs. It ensures not only that we follow the standard model but also ensures the regional presence and cooperation with the sites in any region.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive